Skip to main content

Table 4 Analysis of primary and secondary outcomes

From: A biopsychosocial approach to primary hypothyroidism: treatment and harms data from a randomized controlled trial

Outcome

MCID (±)

Difference between groups 7 weeks (NET-Placebo)

Difference between groups 6 months (NET-Placebo)

Time x group interaction

Mean difference (95 % CI)

P-value

Mean difference (95 % CI)

P-value

P-value

Depression

4

−0.58 (−4.62, 3.45)

0.78

−0.04 (−4.04, 3.96)

0.98

0.60

Anxiety

5

0.63 (−2.19, 3.46)

0.66

0.36 (−2.44, 3.16)

0.80

0.98

Stress

4

0.29 (−3.63, 4.21)

0.88

1.47 (−2.42, 5.35)

0.46

0.86

TSH

0.75

0.11 (−2.64, 2.88)

0.93

1.01 (−1.76, 3.77)

0.47

0.49

FT4

6.0

0.67 (−0.81, 2.15)

0.37

0.33 (−1.14, 1.80)

0.66

0.85

FT3

1.5

0.29 (−0.24, 0.83)

0.28

0.15 (−0.38, 0.68)

0.58

0.82

Physical functioning

3.5

−0.76 (−9.07, 7.56)

0.86

1.75 (−6.41, 9.91)

0.67

0.35

Role physical

3.2

4.25 (−7.31, 15.81)

0.47

4.35 (−6.93, 15.63)

0.45

0.99

Bodily pain

4.5

3.56 (−7.62, 14.73)

0.53

2.35 (−8.43, 13.13)

0.67

0.76

General health

5.7

2.11 (−8.20, 12.43)

0.69

3.35 (−6.78, 13.47)

0.52

0.28

Vitality

5.5

0.27 (−9.76, 10.30)

0.96

−0.10 (−9.84, 9.65)

0.98

0.76

Social functioning

5.0

9.05 (−4.55, 22.66)

0.19

5.58 (−7.54, 18.69)

0.40

0.65

Role emotional

3.8

2.12 (−8.72, 12.96)

0.70

1.13 (−9.36, 11.61)

0.83

0.86

Mental health

5.5

4.73 (−5.23, 14.72)

0.35

4.83 (−4.84, 14.49)

0.33

0.65

Mental component summary

3.1

4.11 (−1.58, 9.79)

0.16

0.22 (−5.25, 5.69)

0.94

0.36

Physical component summary

3.8

1.02 (−3.14, 5.18)

0.63

0.97 (−3.10, 5.03)

0.64

0.50

  1. MCID minimal clinically important difference, TSH thyroid stimulating hormone (mIU/L), FT4 free thyroxine (pmol/L), FT3 Free triiodothyronine (pmol/L)